All News
NIH-Funded Trials Down, While Industry Trials Increase
(Reuters Health) – Every year since 2006 in the U.S., the amount of new medical research in humans funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows.
Read Article
Updated RA Treat-to-Target International Recommendations
In 2010, Smolen and a group of international rheumatologists developed a series of recommendations addressing the concept of treat-to-target (T2T) in the management of rheumatoid arthritis (RA).
Read Article
Risk of Multiple Sclerosis with TNF Inhibitor Therapy
Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi).
Read Article
Biosimilar Reports - January 2016
Biosimilars are the fastest developing product line within the pharmaceutical industry. There is unanimous worldwide interest in the continued use of biologics for immune mediated disorders.
Read Article
TNF Inhibitors May Increase Cardiac Risks in Elderly
A retrospective study of elderly rheumatoid arthritis (RA) patients on Medicare was conducted by a group of researchers from the University of Alabama.
Read Article
PALACE 3 Study: Apremilast Shows 52 Wk. Efficacy in Active Psoriatic Arthritis
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibiting conversion of cyclic AMP to AMP, was approved for treatment of psoriatic arthritis (PsA) after showing its efficacy in 16 weeks PALACE 1, 2, and 3 trials in 2014.
Read Article
FDA Approves Cosentyx for Ankylosing Spondylitis and Psoriatic Arthritis
Cosentyx (secukinumab) was approved by the FDA on 15 January, 2016 for patients with active ankyosing spondylitis (AS) and psoriatic arthritis (PsA).
Read Article
Combination or Monotherapy Tocilizumab in Rheumatoid Arthritis
Several rheumatoid arthritis studies have shown that tocilizumab (TCZ) may be as effective as monotherapy when compared to combination therapy (methotrexate plu
Read Article
Game-Changers 2015: Refining Treatment in Arthritis
Widening experience with JAK inhibition for rheumatoid arthritis (RA) and tapering medications among RA patients in remission, along with the success of secukinumab for psoriatic arthritis (PsA), were the most important advances in rheumatology in 2015, according to specialists responding toMedPa
Read Article
Secukinumab Shows Efficacy in Two Ankylosing Spondylitis Trials
NEJM has published the results of two studies wherein IL-17 inhibition with secukinumab (SEC) was shown to be effective in patients with anklylosing spondylitis.
Read Article
Tofacitinib Shows Promise in Alopecia, Eczema and Vitiligo
Tofacitinib has been approved for use in rheumatoid arthritis.
Read Article
2015 ACR RA Guidelines Released– Finally! (Best of 2015: #2)
ACR 2015 RA treatment guidelines were published yesterday, nearly a year after they were preliminarily presented at the 2014 ACR meeting in Boston. After a year of review and revision these have been posted.
Read Article
The History of Citrullination (Best of 2015)
1998 marked the introduction of citrulline as a unique target in the pathogenesis of rheumatoid arthritis. The hallmark article by Schellekens et al in the Journal of Clinical Investigation has since been cited over 500 times. Dr.
Read Article
How I Choose Biologics (Best of 2015)
Clinical decision-making, occurring at the intersection of the ’art’ and the ’science’ of medicine, remains enigmatic and controversial.
Read Article
Preventing Hepatitis B Reactivation Due to Immunosuppressive Drug Treatments (Best of 2015)
Reactivation of hepatitis B virus infection can have devastating consequences, especially amongst those patients receiving immunosuppressive therapy.
Read Article
DAS28-CRP or DAS28-ESR: Are they Biosimilar? (Best of 2015)
The disease activity score (DAS28) has been developed as a dynamic assessment tool and a therapeutic response measure for use in clinical trials and practice.
Read Article
Will the Balance of JAK inhibition Yield Better Outcomes? Results of New JAK inhibitor - Peficitinib
Researchers from Keio University have published their results using novel JAK inhibitor peficitinib (ASP015K) as a monotherapy in moderate to severe RA patients.
Read Article
Herpes Zoster Increases the Risk of Stroke and MI
At the 2015 ACR annual meeting in San Francisco, Len Calabrese, DO, of the Cleveland Clinic, gave a plenary session talk linking "shingles" infection to an increased risk of CVA (
Read Article
Plasmacytoid Dendritic Cells Influences Early, But Not Established Lupus
The Journal of Immunology has published the findings of Virginia Tech researchers who have studied plasmacytoid dendritic cells and their ability to induce type I alpha interferon (IFN-α) in lupus. (Citation source: http://buff.ly/1MceeCl)
Read Article
RA Guidelines, Methotrexate and Mortal Risks in Gout: November 2015 top social media news
Here's what you may have missed: in November 2015, RheumNow published 80 tweets on news, research and teaching points that impact the rheumatology community. We had a reach (impressions) of 79,100, 79 mentions, and over 3399 visits to RheumNow.com to check out what we publish.
Read Article
